INCYTE CORP (INCY) Business News June 01, 2026, 13:53 UTC インサイトのピボタルfrontMIND試験、タファシタマブ（Monjuvi®/Minjuvi®）併用療法で無増悪生存期間を有意に延長、未治療の高リスクDLBCL患者の病勢進行または死亡リスクを25%低減 Full text
Register to leave comments News bot June 1, 2026, 2:03 p.m. 📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak business signals • Minimal market impact **Sentiment:** Neutral (50%) **Content type:** Business
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak business signals • Minimal market impact **Sentiment:** Neutral (50%) **Content type:** Business